A machine learning model for optimizing treatment of patients with poorly controlled type 2 diabetes
Authors:
Open Access
- 17 February 2026
- journal article
- research article
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Abstract
Background Cardiorenal-protective sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) lack selection guidance. We aimed to build a SGLT-2i/GLP-1RA Decision Score (TiP DecScore) to tailor selection between them. Methods We developed the TiP DecScore in type 2 diabetes (T2D) patients receiving either therapy from the China Metabolic Analytics Project (derivation dataset: n = 24,322; validation dataset: n = 1,459), using gradient boosting decision tree and 15 features. The primary outcomes were glycated haemoglobin (HbA1c) control (1c levels at 6 and 12 months. The model’s clinical effectiveness was evaluated by comparing HbA1c control between concordant (receiving the predicted optimal therapy) and discordant groups (receiving the predicted non-optimal therapy). Results Here we show the derivation cohort has mean (SD) age 53.7 (11.5) years, 63.0% males. Model validation shows good predictive performance (the receiver operating characteristic curve 0.71-0.78). GLP-1RA is favored over SGLT-2i (57.6% vs. 24.2% at 6 months; 57.9% vs. 28.6% at 12 months). At 6 months, compared with SGLT-2i, GLP-1RA is prioritized for patients with a shorter diabetes duration and higher fasting C-peptide, alanine aminotransferase, body mass index (BMI), and low-density lipoprotein cholesterol levels. At 12 months, patients with higher baseline HbA1c and BMI levels are more likely to be recommended GLP-1RA than SGLT-2i. Higher rates of HbA1c control are observed in concordant versus discordant groups, especially in younger patients (<55 years; 64.1% vs. 46.2%, P = 0.001) and males (58.6% vs. 45.6%, P = 0.018) at 12 months. Conclusions The TiP DecScore effectively guides personalized selection between SGLT-2i and GLP-1RA therapies for T2D patients.Keywords
This publication has 43 references indexed in Scilit:
- A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation studyThe Lancet, 2025
- Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesDiabetologia, 2024
- Protecting older people: a high priority during the COVID-19 pandemicThe Lancet, 2022
- Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?Molecular Metabolism, 2021
- Use of radiomics based on 18F-FDG PET/CT and machine learning methods to aid clinical decision-making in the classification of solitary pulmonary lesions: an innovative approachEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial dataThe Lancet Diabetes & Endocrinology, 2019
- Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variablesThe Lancet Diabetes & Endocrinology, 2018
- Lixisenatide as add‐on treatment among patients with different β‐cell function levels as assessed by HOMA‐β indexDiabetes/Metabolism Research and Reviews, 2017
- Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical StudiesCanadian Journal of Diabetes, 2016
- Clinical Effectiveness of Liraglutide Across Body Mass Index in Patients with Type 2 Diabetes in the United States: A Retrospective Cohort StudyAdvances in Therapy, 2014